Immunologic responses to subcutaneous allergen immunotherapy

Allergens and Allergen Immunotherapy, Fourth Edition

Volumn , Issue , 2008, Pages 59-70

  Till, Stephen J ^a   Durham, Stephen R ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10;

ANTIGEN PRESENTING CELL; BASOPHIL; BLOOD; DESENSITIZATION; DRUG ADMINISTRATION ROUTE; EOSINOPHIL; HUMAN; HYPERSENSITIVITY; IMMUNOLOGY; MAST CELL; METABOLISM; REGULATORY T LYMPHOCYTE; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; ALLERGENS; ANTIGEN-PRESENTING CELLS; BASOPHILS; DESENSITIZATION, IMMUNOLOGIC; DRUG ADMINISTRATION ROUTES; EOSINOPHILS; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-10; MAST CELLS; T-LYMPHOCYTES, REGULATORY;

EID: 58149473804     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (73)

1. Ong YE, Menzies-Gow A, Barkans J, et al. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. J Allergy Clin Immunol 2005; 116(3): 558-564.
2. Pienkowski MM, Norman PS, Lichtenstein LM. Suppression of late-phase skin reactions by immunotherapy with ragweed extract. J Allergy Clin Immunol 1985; 76(5): 729-734.
3. Iliopoulos O, Proud D, Adkinson NF Jr., et al. Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells. J Allergy Clin Immunol 1991; 87(4): 855-866.
4. Warner JO, Price JF, Soothill JF, et al. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet 1978; 2(8096): 912-915.
5. Walker SM, Varney VA, Gaga M, et al. Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Allergy 1995; 50(5): 405-413.
6. Des RA, Paradis L, Knani J, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996; 51(6): 430-433.
7. Francis JN, James LK, Paraskevopoulos G, et al. Grass Pollen Immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008; 121(5): 1120-1125.
8. Otsuka H, Mezawa A, Ohnishi M, et al. Changes in nasal metachromatic cells during allergen immunotherapy. Clin Exp Allergy 1991; 21(1): 115-119.
9. Wilson DR, Irani AM, Walker SM, et al. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy 2001; 31(11): 1705-1713.
10. Nouri-Aria KT, Pilette C, Jacobson MR, et al. IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy. J Allergy Clin Immunol 2005; 116(1): 73-79.
11. Varney VA, Hamid QA, Gaga M, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993; 92(2): 644-651.
12. Furin MJ, Norman PS, Creticos PS, et al. Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol 1991; 88(1): 27-32.
13. Durham SR, Ying S, Varney VA, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996; 97(6): 1356-1365.
14. Wilson DR, Nouri-Aria KT, Walker SM, et al. Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. J Allergy Clin Immunol 2001; 107(6): 971-976.
15. Rak S, Lowhagen O, Venge P. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Clin Immunol 1988; 82(3 pt 1): 470-480.
16. Gehlhar K, Schlaak M, Becker W, et al. Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome. Clin Exp Allergy 1999; 29(4): 497-506.
17. Lichtenstein LM, Ishizaka K, Norman PS, et al. IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest 1973; 52(2): 472-482.
18. Moverare R, Elfman L, Vesterinen E, et al. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy 2002; 57(5): 423-430.
19. Platts-Mills TA, von Maur RK, Ishizaka K, et al. IgA and IgG anti-ragweed antibodies in nasal secretions. Quantitative measurements of antibodies and correlation with inhibition of histamine release. J Clin Invest 1976; 57(4): 1041-1050.
20. Jutel M, Akdis M, Budak F, et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003; 33(5): 1205-1214.
21. Garcia BE, Sanz ML, Gato JJ, et al. IgG4 blocking effect on the release of antigen-specific histamine. J Investig Allergol Clin Immunol 1993; 3(1): 26-33.
22. Pilette C, Nouri-Aria KT, Jacobson MR, et al. Grass pollen immunotherapy induces an allergenspecific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol 2007; 178(7): 4658-4666.
23. van Neerven RJ, Wikborg T, Lund G, et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999; 163(5): 2944-2952.
24. Wachholz PA, Soni NK, Till SJ, et al. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003; 112(5): 915-922.
25. van Neerven RJ, Arvidsson M, Ipsen H, et al. A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation. Clin Exp Allergy 2004; 34(3): 420-428.
26. Nouri-Aria KT, Wachholz PA, Francis JN, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004; 172(5): 3252-3259.
27. Djurup R, Malling HJ. High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens. Clin Allergy 1987; 17(5): 459-468.
28. Ewan PW, Deighton J, Wilson AB, et al. Venom-specific IgG antibodies in bee and wasp allergy: lack of correlation with protection from stings. Clin Exp Allergy 1993; 23(8): 647-660.
29. Bodtger U, Ejrnaes AM, Hummelshoj L, et al. Is immunotherapy-induced birch-pollen-specific IgG4 a marker for decreased allergen-specific sensitivity? Int Arch Allergy Immunol 136(4): 340-346.
30. Jutel M, Pichler WJ, Skrbic D, et al. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995; 154(8): 4187-4194.
31. Bellinghausen I, Metz G, Enk AH, et al. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 1997; 27(5): 1131-1139.
32. Ebner C, Siemann U, Bohle B, et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy 1997; 27(9): 1007-1015.
33. Benjaponpitak S, Oro A, Maguire P, et al. The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy. J Allergy Clin Immunol 1999; 103(3 pt 1): 468-475.
34. Till S, Walker S, Dickason R, et al. IL-5 production by allergen-stimulated T cells following grass pollen immunotherapy for seasonal allergic rhinitis. Clin Exp Immunol 1997; 110(1): 114-121.
35. Klimek L, Dormann D, Jarman ER, et al. Short-term preseasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral T-cell responses, in patients with allergic rhinitis. Clin Exp Allergy 1999; 29(10): 1326-1335.
36. Wachholz PA, Nouri-Aria KT, Wilson DR, et al. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1: Th2 cytokine ratios. Immunology 2002; 105(1): 56-62.
37. Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003; 111(6): 1255-1261.
38. Varga EM, Wachholz P, Nouri-Aria KT, et al. T cells from human allergen-induced late asthmatic responses express IL-12 receptor beta 2 subunit mRNA and respond to IL-12 in vitro. J Immunol 2000; 165(5): 2877-2885.
39. Hamid QA, Schotman E, Jacobson MR, et al. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 1997; 99(2): 254-260.
40. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155(3): 1151-1164.
41. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299(5609): 1057-1061.
42. Sakaguchi S, Sakaguchi N. Regulatory T cells in immunologic self-tolerance and autoimmune disease. Int Rev Immunol 2005; 24: 211-226.
43. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000; 192(2): 303-310.
44. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001; 194(5): 629-644.
45. Ling EM, Smith T, Nguyen XD, et al. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004; 363(9409): 608-615.
46. McHugh RS, Whitters MJ, Piccirillo CA, et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002; 16(2): 311-323.
47. Levings MK, Sangregorio R, Roncarolo MG. Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001; 193(11): 1295-1302.
48. Sundstedt A, O’Neill EJ, Nicolson KS, et al. Role for IL-10 in suppression mediated by peptideinduced regulatory T cells in vivo. J Immunol 2003; 170(3): 1240-1248.
49. Barrat FJ, Cua DJ, Boonstra A, et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2- inducing cytokines. J Exp Med 2002; 195(5): 603-616.
50. Vieira PL, Christensen JR, Minaee S, et al. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+regulatory T cells. J Immunol 2004; 172(10): 5986-5993.
51. Akdis CA, Blesken T, Akdis M, et al. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998; 102(1): 98-106.
52. Tournoy KG, Kips JC, Pauwels RA. Endogenous interleukin-10 suppresses allergen-induced airway inflammation and nonspecific airway responsiveness. Clin Exp Allergy 2000; 30(6): 775-783.
53. Jeannin P, Lecoanet S, Delneste Y, et al. IgE versus IgG4 production can be differentially regulated by IL-10. J Immunol 1998; 160(7): 3555-3561.
54. Royer B, Varadaradjalou S, Saas P, et al. Inhibition of IgE-induced activation of human mast cells by IL-10. Clin Exp Allergy 2001; 31(5): 694-704.
55. Groux H, Bigler M, de Vries JE, et al. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+T cells. J Exp Med 1996; 184(1): 19-29.
56. Akdis CA, Joss A, Akdis M, et al. A molecular basis for T cell suppression by IL-10: CD28-associated IL-10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3-kinase binding. FASEB J 2000; 14(12): 1666-1668.
57. Akbari O, DeKruyff RH, Umetsu DT. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001; 2(8): 725-731.
58. Zhang X, Izikson L, Liu L, et al. Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration. J Immunol 2001; 167(8): 4245-4253.
59. Akbari O, Freeman GJ, Meyer EH, et al. Antigen-specific regulatory T cells develop via the ICOSICOS- ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med 2002; 8(9): 1024-1032.
60. Ito T, Yang M, Wang YH, et al. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med 2007; 204(1): 105-115.
61. Novak N, Allam JP, Hagemann T, et al. Characterization of FcepsilonRI-bearing CD123 blood dendritic cell antigen-2 plasmacytoid dendritic cells in atopic dermatitis. J Allergy Clin Immunol 2004; 114(2): 364-370.
62. Nopp A, Hallden G, Lundahl J, et al. Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen bet v 1 and to recombinant bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients. J Allergy Clin Immunol 2000; 106(1 pt 1): 101-109.
63. Hage-Hamsten M, Johansson E, Roquet A, et al. Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild-type in patients with allergic rhinitis. Clin Exp Allergy 2002; 32(10): 1448-1453.
64. Niederberger V, Horak F, Vrtala S, et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A 2004; 101(suppl 2): 14677-14682.
65. Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002; 360(9326): 47-53.
66. Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006; 117(1): 134-140.
67. Marshall JD, Abtahi S, Eiden JJ, et al. Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. J Allergy Clin Immunol 2001; 108(2): 191-197.
68. Moseman EA, Liang X, Dawson AJ, et al. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+regulatory T cells. J Immunol 2004; 173(7): 4433-4442.
69. Creticos PS, Schroeder JT, Hamilton RG, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355(14): 1445-1455.
70. Puggioni F, Durham SR, Francis JN. Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favor of Th1 responses. Allergy 2005; 60(5): 678-684.
71. Drachenberg KJ, Wheeler AW, Stuebner P, et al. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001; 56(6): 498-505.
72. Shamji MH, Wilcock LK, Wachholz PA, et al. The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods 2006; 317(1-2): 71-79.
73. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005; 60(1): 4-12.